世界の電子ドラッグデリバリーシステム市場2022-2029:種類別(ウェアラブル輸液ポンプ、自動注射器、注射ペン、吸入器)、疾患別、地域別

【英語タイトル】Global Electronic Drug Delivery Systems Market Size study & Forecast, by Type (Wearable Infusion Pumps, Autoinjectors, Injection Pens and Inhalers), by Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD and Other Indications) and Regional Analysis, 2022-2029

Bizwit Research & Consultingが出版した調査資料(BZW23MR079)・商品コード:BZW23MR079
・発行会社(調査会社):Bizwit Research & Consulting
・発行日:2023年2月18日
・ページ数:約200
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥925,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Bizwit Research社の本調査レポートは、2021年に92.5億ドルであった世界の電子ドラッグデリバリーシステム市場規模が、2022年から2029年の間に8.9%成長すると予想しています。本レポートでは、電子ドラッグデリバリーシステムの世界市場について調査し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、種類別(ウェアラブル輸液ポンプ、自動注射器、注射ペン、吸入器)分析、疾患別(糖尿病、多発性硬化症、心血管疾患、喘息・COPD、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、その他)分析、競争状況、調査プロセスなどの項目を掲載しています。また、本書には、Biogen Inc、United Therapeutics Corporation、Medtronic PLC、Bayer AG、Insulet Corporation、Novo Nordisk、Companion Medical、F.Hoffmann-La Roche, Ltd.、Amgen, Inc.、AstraZeneca PLC などの企業情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析(新型コロナウイルス感染症の影響)
・世界の電子ドラッグデリバリーシステム市場規模:種類別
- ウェアラブル輸液ポンプの市場規模
- 自動注射器の市場規模
- 注射ペンの市場規模
- 吸入器の市場規模
・世界の電子ドラッグデリバリーシステム市場規模:疾患別
- 糖尿病の市場規模
- 多発性硬化症の市場規模
- 心血管疾患の市場規模
- 喘息・COPDの市場規模
- その他疾患の市場規模
・世界の電子ドラッグデリバリーシステム市場規模:地域別
- 北米の電子ドラッグデリバリーシステム市場規模
- ヨーロッパの電子ドラッグデリバリーシステム市場規模
- アジア太平洋の電子ドラッグデリバリーシステム市場規模
- 中南米の電子ドラッグデリバリーシステム市場規模
- その他地域の電子ドラッグデリバリーシステム市場規模
・競争状況
・調査プロセス

Global Electronic Drug Delivery Systems Market is valued approximately USD 9.25 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.9% over the forecast period 2022-2029. Electronic drug delivery systems are portable devices that offer convenient options to patients, such as easy drug administration, dose accuracy, short administration time, and improved patient adherence. The Electronic Drug Delivery Systems market is expanding because of factors such as rising diabetes prevalence and growing geriatric population. It’s an oligopolistic market dominated by Novo Nordisk A/S, and AstraZeneca PLC.

Diabetes is one of the world’s fastest-growing chronic diseases. Its prevalence has progressively increased during the last few decades. According to the World Health Organization, diabetes will afflict 537 million adults globally in 2021, with one in ten experiencing other diabetes. Furthermore, geriatric, and obese populations are predisposed to chronic diseases. According to the World Bank Group, the world old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. Another important component driving space is the rising technological advancements in development of smart drug delivery systems. As per Statista, the market size of drug delivery devices across India was forecasted to value around USD 510 million by 2023. In addition, in 2019, the total global cell and gene drug delivery devices market was dominated by North America and Europe, which were responsible for than 83 % of the market all together. It was forecast that this domination will continue until 2030. However, availability of alternative drug delivery modes stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Electronic Drug Delivery Systems Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the Increased demand for advanced drug delivery systems such as metered-dose inhalers and sensor-embedded devices. According to the Statista, as of 2021, the United States’ share of the total global biotech value stood at nearly 59 %, while China had around 11%. Furthermore, Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an rise in diabetic patients and the high demand for advanced healthcare services in the market space.

Major market player included in this report are:
Biogen Inc
United Therapeutics Corporation
Medtronic PLC
Bayer AG
Insulet Corporation
Novo Nordisk
Companion Medical
F.Hoffmann-La Roche, Ltd.
Amgen, Inc.
AstraZeneca PLC

Recent Developments in the Market:
 In January 2023, Biogen partnered with Alcyone Therapeutics to improve the delivery of its spinal muscular atrophy drug Spinraza, handing over USD 10 million upfront for a global license to an implantable device. It is delivered via intrathecal injection, also known as lumbar puncture. The route of delivery gets the antisense oligonucleotide into the cerebrospinal fluid and thereby provides direct access to motor neurons in the central nervous system. But intrathecal injections can be uncomfortable for patients and require travel to hospitals or outpatient clinics.

Global Electronic Drug Delivery Systems Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Indication, Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Wearable Infusion Pumps
Autoinjectors
Injection Pens
Inhalers

By Indication:
Diabetes
Multiple Sclerosis
Cardiovascular Disease
Asthma & COPD
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

❖ レポートの目次 ❖

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Electronic Drug Delivery Systems Market, by Region, 2019-2029 (USD Billion)
1.2.2. Electronic Drug Delivery Systems Market, by Type, 2019-2029 (USD Billion)
1.2.3. Electronic Drug Delivery Systems Market, by Indication, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Electronic Drug Delivery Systems Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Electronic Drug Delivery Systems Market Dynamics
3.1. Electronic Drug Delivery Systems Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of chronic diseases
3.1.1.2. Growing geriatric population
3.1.2. Market Challenges
3.1.2.1. Availability of alternative drug delivery modes
3.1.3. Market Opportunities
3.1.3.1. Rising technological advancements in development of smart drug delivery systems.

Chapter 4. Global Electronic Drug Delivery Systems Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Electronic Drug Delivery Systems Market, by Type
6.1. Market Snapshot
6.2. Global Electronic Drug Delivery Systems Market by Type, Performance – Potential Analysis
6.3. Global Electronic Drug Delivery Systems Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Electronic Drug Delivery Systems Market, Sub Segment Analysis
6.4.1. Wearable Infusion Pumps
6.4.2. Autoinjectors
6.4.3. Injection Pens
6.4.4. Inhalers
Chapter 7. Global Electronic Drug Delivery Systems Market, by Indication
7.1. Market Snapshot
7.2. Global Electronic Drug Delivery Systems Market by Indication, Performance – Potential Analysis
7.3. Global Electronic Drug Delivery Systems Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
7.4. Electronic Drug Delivery Systems Market, Sub Segment Analysis
7.4.1. Diabetes
7.4.2. Multiple Sclerosis
7.4.3. Cardiovascular Disease
7.4.4. Asthma & COPD
7.4.5. Others
Chapter 8. Global Electronic Drug Delivery Systems Market, Regional Analysis
8.1. Electronic Drug Delivery Systems Market, Regional Market Snapshot
8.2. North America Electronic Drug Delivery Systems Market
8.2.1. U.S. Electronic Drug Delivery Systems Market
8.2.1.1. Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. Indication breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Electronic Drug Delivery Systems Market
8.3. Europe Electronic Drug Delivery Systems Market Snapshot
8.3.1. U.K. Electronic Drug Delivery Systems Market
8.3.2. Germany Electronic Drug Delivery Systems Market
8.3.3. France Electronic Drug Delivery Systems Market
8.3.4. Spain Electronic Drug Delivery Systems Market
8.3.5. Italy Electronic Drug Delivery Systems Market
8.3.6. Rest of Europe Electronic Drug Delivery Systems Market
8.4. Asia-Pacific Electronic Drug Delivery Systems Market Snapshot
8.4.1. China Electronic Drug Delivery Systems Market
8.4.2. India Electronic Drug Delivery Systems Market
8.4.3. Japan Electronic Drug Delivery Systems Market
8.4.4. Australia Electronic Drug Delivery Systems Market
8.4.5. South Korea Electronic Drug Delivery Systems Market
8.4.6. Rest of Asia Pacific Electronic Drug Delivery Systems Market
8.5. Latin America Electronic Drug Delivery Systems Market Snapshot
8.5.1. Brazil Electronic Drug Delivery Systems Market
8.5.2. Mexico Electronic Drug Delivery Systems Market
8.5.3. Rest of Latin America Electronic Drug Delivery Systems Market
8.6. Rest of The World Electronic Drug Delivery Systems Market

Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Biogen Inc.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. United Therapeutics Corporation
9.2.3. Medtronic PLC
9.2.4. Bayer AG
9.2.5. Insulet Corporation
9.2.6. Novo Nordisk
9.2.7. Companion Medical
9.2.8. F.Hoffmann-La Roche, Ltd.
9.2.9. Amgen, Inc.
9.2.10. Astrazeneca PLC

Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption



★調査レポート[世界の電子ドラッグデリバリーシステム市場2022-2029:種類別(ウェアラブル輸液ポンプ、自動注射器、注射ペン、吸入器)、疾患別、地域別] (コード:BZW23MR079)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の電子ドラッグデリバリーシステム市場2022-2029:種類別(ウェアラブル輸液ポンプ、自動注射器、注射ペン、吸入器)、疾患別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆